{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:24:10Z","timestamp":1785929050936,"version":"3.56.0"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:00:00Z","timestamp":1708819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>In December 2021, enfortumab vedotin (EV), an antibody\u2010drug conjugate directed against nectin\u20104, was approved in Japan as a new treatment after platinum\u2010containing chemotherapy and PD\u20101\/PD\u2010L1 inhibitors. This study evaluated, using real\u2010world data, the efficacy and safety of EV therapy in patients with metastatic urothelial carcinoma (mUC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Fifty\u2010five patients with mUC who discontinued pembrolizumab therapy due to disease progression between June 2018 and April 2023 at Yokohama City University Hospital were evaluated retrospectively. Of the 55 patients, 25 received EV therapy (EV group) and 30 did not (non\u2010EV group). All patients who underwent EV therapy were diagnosed with disease progression after the approval of EV in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median (range) follow\u2010up period after pembrolizumab discontinuation was 6.3 (0.7\u201331.1) months. There were eight (32.0%) deaths due to cancer in the EV group and 27 (90.0%) in the non\u2010EV group. The overall survival (OS) after pembrolizumab discontinuation was not reached in the EV group versus 2.6\u2009months in the non\u2010EV group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). A multivariate analysis revealed that EV therapy (EV vs. non\u2010EV group; hazard ratio 0.26; 95% confidence interval 0.16\u20130.41; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) was an independent prognostic factor for OS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>EV prolonged OS in mUC following pembrolizumab therapy in real\u2010world data.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.15437","type":"journal-article","created":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T08:43:57Z","timestamp":1708850637000},"page":"678-684","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real\u2010world data"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5761-3508","authenticated-orcid":false,"given":"Koichi","family":"Uemura","sequence":"first","affiliation":[{"name":"Department of Urology Yokohama City University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Urology Yokohama City University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Jikuya","sequence":"additional","affiliation":[{"name":"Department of Urology Yokohama City University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Urology Yokohama City University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-4975","authenticated-orcid":false,"given":"Tomoyuki","family":"Tatenuma","sequence":"additional","affiliation":[{"name":"Department of Urology Yokohama City University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-3379","authenticated-orcid":false,"given":"Takashi","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation Yokohama City University Medical Center  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Urology Yokohama City University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Komeya","sequence":"additional","affiliation":[{"name":"Department of Urology Yokohama City University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6055-1857","authenticated-orcid":false,"given":"Kentaro","family":"Muraoka","sequence":"additional","affiliation":[{"name":"Department of Urology Yokohama City University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Hasumi","sequence":"additional","affiliation":[{"name":"Department of Urology Yokohama City University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation Yokohama City University Medical Center  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7449-2015","authenticated-orcid":false,"given":"Kazuhide","family":"Makiyama","sequence":"additional","affiliation":[{"name":"Department of Urology Yokohama City University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,25]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5165"},{"key":"e_1_2_12_3_1","first-page":"31","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European multicenter real\u2010world patient cohort","volume":"53","author":"Zschabitz S","year":"2023","journal-title":"Eur Urol"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34057"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad170"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15368"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092243"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14861"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.016"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1865910"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00844-x"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.621591"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.07.014"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.15437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:05:11Z","timestamp":1717571111000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.15437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,25]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/iju.15437"],"URL":"https:\/\/doi.org\/10.1111\/iju.15437","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,25]]},"assertion":[{"value":"2023-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}